NVG-291 in Spinal Cord Injury Subjects
About this trial
This trial is enrolling 40 individuals with chronic (1-10 years) and subacute (10-49 days) cervical spinal cord injuries to test the safety and effect of an experimental drug, NVG-291. If included, participants will receive a daily subcutaneous (under the skin) injection for 14 days of either: 1) NVG-291; or 2) a placebo drug. In lab studies, NVG-291 improved locomotion and bladder recovery. Final testing of spinal cord electrical activity (electrophysiology) as well as upper and lower limb function will be assessed after 16 weeks.
Included participants
Traumatic
What’s involved
Type
Details
- participants will receive either a single injection of 1) NVG-291 or 2) a placebo drug, under the skin. - Final testing of upper and lower limb function will be assessed after 16 weeks.
Potential benefits
Main benefits
Standing/walking/mobility
Additional benefits
Arm/hand function
General health
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more- Trial recruitment status
- Recruiting
- Trial start date
- 8 Aug 2023
- Organisation
- NervGen Pharma
- Trial recruitment status
- Recruiting
- Trial start date
- 8 Aug 2023
- Organisation
- NervGen Pharma
About this trial
Included participants
What’s involved
Potential benefits
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more